Project Grant R43GM143955
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,401,149 to The Regents of the University of California, doing business as the University of California, Berkeley (UC Berkeley), to develop small molecule ligands that can modulate major histocompatibility complex (MHC) proteins. The goal is to enhance the presentation of cancer antigens by MHC Class I proteins and block antigen...
- Vcreate, Inc. was awarded a $256,000 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a high-throughput platform for discovering T-cell receptor (TCR) based immunotherapies for late-stage cancer patients. The platform aims to screen thousands of TCRs against thousands of cancer antigens to identify clinically relevant TCRs that could serve as the basis for new treatments against currently incurable cancers....
- Federal Grant Award Summary Massachusetts Institute of Technology received a $414,803 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded on July 18, 2025, with completion targeted for June 30, 2027. The research focuses on directed evolution of T cell receptors (TCRs) with improved antigen sensitivity to enhance the efficacy and safety of TCR-T cell immunotherapies for cancer treatment. The project will implement high-throughput...
- Federal Project Grant Summary Seattle Children's Research Institute received a $434,361 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2027. The award funds the development of multispecific T cell engaging (MTE) therapy targeting mixed-phenotype acute leukemia (MPAL), a high-risk leukemia subtype with poor prognosis, particularly in adult patients over 40 years of age where overall...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded MD Anderson Cancer Center a Project Grant totaling $528,157 (Award Date: September 1, 2025; Completion Date: August 31, 2030) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and apply an artificial intelligence-based foundation model for predicting T cell receptor (TCR)-antigen interactions. The award supports three primary deliverables: (1)...
- The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a Project Grant of $680,597 under the Cancer Biology Research program (CFDA 93.396) for the period April 1, 2026 through March 31, 2031. This award supports fundamental research investigating genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screening in human T cells to identify G-protein coupled receptor (GPCR) pathway targets that enhance chimeric antigen...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a Project Grant of $276,264 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct investigator-initiated biomedical research on the role of T Cell Factor 1 (TCF1) in CD8+ tissue-resident memory T cell (TRM) formation and maintenance across distinct tissues. The research, which commenced on May 13, 2025 and is scheduled for...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,181,683 to the Dana-Farber Cancer Institute in Boston, MA to conduct research aimed at enhancing immune checkpoint blockade responsiveness and tertiary lymphoid structure formation through CD4+TFHx13 CAR-T cells to achieve cures for clear cell renal cell carcinoma (CCRCC). The research will involve experimental design and computational analysis of...
- This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,008,091 to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, to develop a high-throughput and multiplex platform for engineering TCR-Tregs for ALS therapy. The award term runs from May 1, 2024 to April 30, 2026. Columbia University will work with a sub-grantee, Mayo Clinic Arizona, to generate...
- Federal Grant Award Summary Nightstar Biotechnologies, Inc. received a $720,884 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize T-cell receptor (TCR)-T cell therapeutics for cholangiocarcinoma treatment. The award, effective September 18, 2025, with completion by August 31, 2026, supports the company's development of PMTNet, an artificial intelligence foundation model designed to predict interactions between...
COMPUTATIONAL ALGORITHM TO PREDICT INTERACTING MHC ALLELES FROM TCR SEQUENCES - ABSTRACT MAJOR HISTOCOMPATIBILITY COMPLEXES (MHC) GUIDE IMMUNE RESPONSE BY PRESENTING ANTIGEN FRAGMENTS ON A CELL'S SURFACE AND INTERACTING WITH T-CELL RECEPTORS (TCRS). IN RECENT YEARS, MANY T-CELL THERAPIES HAVE SUCCESSFULLY ENGINEERED T-CELLS TO TARGET MHC-ANTIGEN COMPLEXES ASSOCIATED WITH CANCERS AND OTHER DISEASES. HOWEVER, MOST T-CELL THERAPIES REQUIRE IDENTIFYING A TCR THAT INTERACTS WITH AN MHC-ANTIGEN COMPLEX OF INTEREST, A SLOW AND EXPENSIVE SEARCH PROCESS. OUR PROPOSAL AIMS TO SPEED UP THIS SEARCH PROCESS THROUGH A COMPUTATIONAL ALGORITHM THAT WILL PREDICT WHETHER A TCR WILL INTERACT WITH AN MHC ALLELE OF INTEREST. CURRENT SCREENING ASSAYS FOR LOW FREQUENCY TCRS HAVE HIGH FALSE POSITIVE RATES. RESEARCHERS CAN USE OUR TOOL TO COMPUTATIONALLY FILTER TCR CANDIDATES FOR INTERACTION WITH A SPECIFIC MHC ALLELE BEFORE RUNNING EXPENSIVE VALIDATION EXPERIMENTS. IN THIS PROPOSAL, WE WILL FIRST VALIDATE OUR APPROACH THROUGH A PROTOTYPE ALGORITHM THAT WE WILL TRAIN ON PUBLIC TCR-MHC INTERACTION DATA. WE WILL THEN CONDUCT NEW TETRAMER STAINING EXPERIMENTS THAT ADDRESS TWO MAJOR CHALLENGES FOR DEVELOPING AN ALGORITHM ACROSS MULTIPLE MHC ALLELES: THE LACK OF INTERACTION DATA FOR ALLELES OTHER THAN A*02, AND THE LIMITED ANTIGEN DIVERSITY IN EXISTING PUBLIC DATA. THESE EXPERIMENTS WILL PROVIDE TCR-MHC DATA ACROSS 800 ANTIGENS FOR FOUR COMMON MHC ALLELES: A*01:01, A*02:01, A*11:01, AND B*07:02. FINALLY, WE WILL CONSTRUCT AND VALIDATE COMPUTATIONAL ALGORITHMS FOR EACH MHC ALLELE AND EVALUATE THE IMPORTANCE OF VARIOUS TCR COMPONENTS (E.G., ALPHA OR BETA CHAN, CDR3) IN PREDICTING TCR-MHC INTERACTION. OUR WORK WILL RESULT IN THE FIRST COMPUTATIONAL TOOL TO HELP T-CELL THERAPY DEVELOPERS FILTER TCR CANDIDATES BASED ON MHC SPECIFICITY. BEYOND CELL THERAPIES, THIS TOOL WILL ALSO HELP RESEARCHERS TRACK T-CELLS IN DISEASES WHERE MHC ALLELES PLAY A MAJOR ROLE.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/28/23 | ||
| Not listed | $256.6k | 2/2/22 | ||
| Not listed | $256.6k | 2/2/22 |